Adam Levy
Investor Relations Contact presso ALAUNOS THERAPEUTICS, INC.
Profilo
Adam D.
Levy is currently the Executive Director-Investor Relations at Gilead Sciences, Inc., the Director at Vesselon, Inc., the Senior VP-Communications & Investor Relations at Turning Point Therapeutics, Inc., the EVP-Corporate Development & Investor Relations at Alaunos Therapeutics, Inc., and the SVP, Head-Investor Relations & Corporate Affairs at Acrivon Therapeutics, Inc. Previously, he worked as the Senior Vice President-Investor Relations at Zentalis Pharmaceuticals, Inc. Dr. Levy completed his undergraduate and doctorate degrees at the University of Illinois and holds an MBA from the Kellogg School of Management.
Posizioni attive di Adam Levy
| Società | Posizione | Inizio |
|---|---|---|
| ALAUNOS THERAPEUTICS, INC. | Investor Relations Contact | 01/11/2020 |
| TURG POIN | Investor Relations Contact | 08/11/2021 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
| ACRIVON THERAPEUTICS, INC. | Investor Relations Contact | 20/07/2023 |
Vesselon, Inc.
 Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Director/Board Member | - |
Precedenti posizioni note di Adam Levy
| Società | Posizione | Fine |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Formazione di Adam Levy
| University of Illinois | Doctorate Degree |
| Kellogg School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Vesselon, Inc.
Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Health Technology |
- Borsa valori
- Insiders
- Adam Levy
